Current Report Filing (8-k)
September 08 2020 - 04:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 3,
2020
BIOSTAGE, INC.
(Exact name of registrant as specified in its charter)
Delaware |
001-35853 |
45-5210462 |
(State or other jurisdiction
of incorporation)
|
(Commission File Number) |
(IRS Employer Identification No.) |
84 October Hill Road, Suite 11, Holliston,
MA |
01746 |
(Address of principal executive
offices) |
(Zip
Code) |
Registrant's telephone number, including area code: (774)
233-7300
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
¨ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
¨ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
¨ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
|
¨ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
None
Title of each class |
Trading Symbol(s) |
Name of each exchange on which
registered |
|
|
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
x
Item 5.02. Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On September 3, 2020, Jeffrey Young notified the Chairman of the
Board of Directors of Biostage, Inc. (the “Company”) of his
intention to resign as a director of the Company, effective
immediately. At the time of his resignation, Mr. Young was the
chair of the Company’s Audit Committee. The Company is actively in
the process of identifying a qualified candidate to replace Mr.
Young on the Board and its Audit Committee.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the Registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
|
BIOSTAGE,
INC. |
|
|
(Registrant) |
|
|
|
September 8, 2020 |
|
/s/ Hong Yu |
(Date) |
|
Hong Yu |
|
|
President |